SCHEMBL26348162

SCHEMBL26348162

Cc1cc(N2CCC(NCc3ccccc3)CC2)nc(Cl)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.58
KMT2A Q03164 4/20 0.58
ALDH1A1 P00352 2/20 0.58
LMNA P02545 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
HTT P42858 2/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C19 P33261 1/20 0.52
ACHE P22303 9/20 0.51
BACE1 P56817 9/20 0.51
BCHE P06276 7/20 0.51
POLB P06746 1/20 0.51
PKM P14618 1/20 0.50
TSHR P16473 1/20 0.50
CRHBP P24387 1/20 0.50
PIK3CB P42338 1/20 0.50
CRHR2 Q13324 1/20 0.50
CARM1 Q86X55 1/20 0.46
PRMT6 Q96LA8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26346371 0.86 PRMT6 (0.46) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL29442422 0.86 PRMT6 (0.46) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL26346156 0.86 MEN1 (0.58) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL26348174 0.83 ALDH1A1 (0.48) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL26348201 0.79 HRH4 (0.55) MEN1KMT2ALMNACYP1A2CYP2D6
SCHEMBL26348556 0.79 HRH4 (0.55) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL31646673 0.77 ALDH1A1 (0.46) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL26348679 0.76 HRH4 (0.50) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL20692326 0.76 HRH4 (0.56) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL26348587 0.76 ACHE (0.56) MEN1KMT2AALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303512-A1 MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303512-A1 MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF MYB, MYBBP1A, MYCBP MEN1 3806/4885KMT2A 502/4885ALDH1A1 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.